Disqualified from the last Tour de France (which he finished in 6th place) for having tested positive for tramadol twice, Nairo Quintana appealed to the CAS to challenge the UCI sentence. After deliberating its decision on October 12 after Quintana’s appearance, the CAS decided on Thursday to reject the Colombian’s appeal, thus giving reason to the UCI.
Despite his disqualification on the Tour and while he will no longer wear the colors of the Arkéa-Samsic team next year, Quintana is nevertheless still authorized to race.
“This decision reinforces the validity of the ban on tramadol provided for in the UCI medical regulations”
At the end of the decision, the UCI was satisfied with the verdict rendered this Thursday by the Court of Arbitration for Sport. “The International Cycling Union welcomes the sentence handed down today by the Court of Arbitration for Sport (CAS) confirming the disqualification from the Tour de France 2022 of the Colombian rider Nairo Alexander Quintana Rojas for a breach of the ban on the use of tramadol in competition, the UCI said in a statement. This decision reinforces the validity of the ban on tramadol provided for in the UCI medical regulations with the aim of preserving the health and safety of riders. »
The UCI had banned the use of tramadol in competition since March 1, 2019, while the World Anti-Doping Agency (WADA) decided to include it on the list of prohibited products from 2024.